Abiraterone shows activity in hormone-refractory prostate ca

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

Abiraterone, an agent that inhibits an enzyme critical to the production of male hormones, showed anti-tumor activity in men with hormone-refractory prostate cancer (HRPC)

LUGANO, Switzerland—Abiraterone, an agent that inhibits an enzyme critical to the production of male hormones, showed anti-tumor activity in men with hormone-refractory prostate cancer (HRPC), according to two studies presented at ESMO 2007.

Abiraterone, being developed by Cougar Biotechnology, Los Angeles, is an orally active inhibitor of the steroidal enzyme 17-alpha-hydroxylase/c17/20 lyase (CYP450c17), a cytochrome p450 complex that is involved in testosterone production. In preclinical studies, the agent has shown the ability to selectively inhibit the target enzyme, resulting in inhibition of testosterone production in both the adrenals and the testes.

Alison Reid, MD, of the UK's Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, reported results of an ongoing phase I/II trial of chemotherapy-na?ve prostate cancer patients who had progressive disease despite treatment with LHRH analogs and multiple other hormonal therapies. To date, 47 patients have been treated with abiraterone. The agent has been well tolerated at doses as high as 2,000 mg/d with minimal toxicity, Dr. Reid said, adding that no dose-limiting toxicity has been observed to date.

Of the 38 evaluable patients, 33 (87%) had a decline in PSA level: 23 (61%) had a confirmed decline of greater than 50%, while 10 (26%) had a decline of greater than 90%.

Of the 20 evaluable patients with measurable tumor lesions, treatment with abiraterone resulted in a partial radiological response in 11 patients (55%). Seven patients have ongoing stable disease and three have regressing bone disease.

Individual patients also showed improvement in pain and a reduction in opioid use, Dr. Reid said.

For the evaluable patients, the median time to PSA progression has not been reached and is currently estimated to be 8.4 months. At the time of the presentation, 21 of the evaluable patients (55%) remained on study.

Docetaxel-Treated Patients

Gerhardt Attard, MD, from the same UK institutions as Dr. Reid, reported on a phase II trial of HRPC patients who have failed docetaxel (Taxotere)-based chemotherapy. The trial is being conducted at numerous locations in the United States and the United Kingdom, and Dr. Attard reported on the 30 patients who have been treated in the UK.

Of the 21 patients who have been in the study for more than 3 months, 10 (48%) had a confirmed decline in PSA levels of greater than 50% and 2 (10%) had declines of greater than 90%. Of the 12 evaluable patients with measurable tumor lesions, 2 (17%) had a confirmed partial radiological response, 1 had an unconfirmed partial response, and 5 had ongoing stable disease. Of the 43 patients enrolled in the trial, 28 are still receiving treatment with abiraterone.

Related Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content